(RSPH) Invesco SP500 Equal Weight - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46137V3327 • Health
RSPH: Pharmaceuticals, Biotechnology, Medical, Devices, Equipment, Services
The Invesco S&P 500 Equal Weight Health Care ETF (NYSE ARCA: RSPH) is designed to provide exposure to the healthcare sector by tracking the performance of the S&P 500 Equal Weight Health Care Index. This index includes all companies classified under the health care sector within the S&P 500, adhering to the Global Industry Classification Standard (GICS®). The fund typically invests at least 90% of its total assets in securities that make up the underlying index, ensuring a high level of alignment with the indexs performance.
As a healthcare-focused ETF, RSPH offers investors a targeted way to gain exposure to a broad range of companies within the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and health care providers. The equal-weight approach distinguishes it from market-capitalization-weighted funds, as each company in the index has a similar influence on the funds performance, regardless of its size. This can be appealing for investors seeking more balanced exposure to the sector.
With assets under management (AUM) of $821.92 million, RSPH is a moderately sized ETF, which can indicate a balance between liquidity and diversification. The fund trades on the NYSE ARCA exchange, a platform known for its efficiency in listing and trading ETFs. RSPH is categorized under the health care sector, making it a straightforward option for investors looking to allocate to this specific area of the market.
Looking ahead, the healthcare sector is poised for continued evolution, driven by demographic shifts, technological advancements, and regulatory changes. The equal-weight approach of RSPH may allow it to capitalize on emerging trends and innovations across the sector, as smaller, innovative companies may have a more significant impact on the funds performance compared to a market-cap-weighted alternative. However, the sectors sensitivity to policy changes and regulatory developments, particularly in the U.S., could introduce volatility. As interest rates and broader market conditions evolve, RSPHs performance will likely reflect the interplay between sector-specific dynamics and macroeconomic factors.
Additional Sources for RSPH ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RSPH ETF Overview
Market Cap in USD | 821m |
Category | Health |
TER | 0.40% |
IPO / Inception | 2006-11-01 |
RSPH ETF Ratings
Growth 5y | 52.5% |
Fundamental | - |
Dividend | 57.1% |
Rel. Strength Industry | -13.4 |
Analysts | - |
Fair Price Momentum | 28.89 USD |
Fair Price DCF | - |
RSPH Dividends
Dividend Yield 12m | 0.70% |
Yield on Cost 5y | 1.24% |
Annual Growth 5y | 9.63% |
Payout Consistency | 95.9% |
RSPH Growth Ratios
Growth Correlation 3m | 38.7% |
Growth Correlation 12m | 2.2% |
Growth Correlation 5y | 71.7% |
CAGR 5y | 11.75% |
CAGR/Max DD 5y | 0.54 |
Sharpe Ratio 12m | -1.66 |
Alpha | -12.27 |
Beta | 0.45 |
Volatility | 15.15% |
Current Volume | 49.6k |
Average Volume 20d | 71k |
As of March 14, 2025, the stock is trading at USD 29.38 with a total of 49,558 shares traded.
Over the past week, the price has changed by -3.39%, over one month by -2.94%, over three months by -2.24% and over the past year by -6.24%.
Partly, yes. Based on ValueRay Analyses, Invesco SP500 Equal Weight (NYSE ARCA:RSPH) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 52.53 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RSPH as of March 2025 is 28.89. This means that RSPH is currently overvalued and has a potential downside of -1.67%.
Invesco SP500 Equal Weight has no consensus analysts rating.
According to ValueRays Forecast Model, RSPH Invesco SP500 Equal Weight will be worth about 31.6 in March 2026. The stock is currently trading at 29.38. This means that the stock has a potential upside of +7.39%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 31.6 | 7.4% |